H cause of morbidity after cardiac operations [l, 21. A
|
|
- Elmer Alexander Scott
- 6 years ago
- Views:
Transcription
1 Reduction of Heparin Binding to and Inhibition of Platelets by Aprotinin Lindsay C. H. John, FRCS, Gareth M. Rees, FRCS, and Iren B. Kovacs, FRCPath Department of Cardiothoracic Surgery and the Thrombosis Unit, St. Bartholomew s Hospital, London, England The direct effect of aprotinin on in vitro platelet function was assessed by hemostatometry (n = 10). No significant enhancement was demonstrated. However, aprotinin reduced platelet inhibition secondary to heparin. Hemostatometry demonstrated a significant preservation of in vitro platelet function (n = 25) (p = 0.04), which was particularly marked (p = 0.003) in the subgroup (n = 7) demonstrating a severe inhibition of platelet function with heparin. Aprotinin significantly reduced the bind- ing of tritium-labeled heparin to both nonactivated (n = 25) (p = 0.004) and activated platelets (n = 25) (p < ). We conclude that interference with heparininduced inhibition of platelet function by aprotinin may be one of its hemostatic actions in cardiac surgery. This effect is probably secondary to aprotinin reducing binding of heparin to platelets. (Ann Thorac Surg 1993;55:1175-9) emorrhage after cardiopulmonary bypass is a major H cause of morbidity after cardiac operations [l, 21. A chief factor in this appears to be an acquired platelet dysfunction [l, 3,4]. One cause recently identified for this dysfunction is the use of heparin [5], which is an essential prerequisite for cardiopulmonary bypass. Aprotinin has been clearly demonstrated to reduce hemorrhage after bypass [6-81. A number of actions of aprotinin have been suggested to explain its hemostatic action, including preservation of platelet function during bypass [7]. Theoretically aprotinin may have such a beneficial effect either by a direct action enhancing platelet function or by an indirect action protecting the platelets from an inhibitory consequence of cardiopulmonary bypass. To date, however, in vitro tests of platelet function and coagulation have failed to show any hemostatic action with aprotinin. On the contrary, platelet aggregation was inhibited by esterase inhibitors including aprotinin [9, 101. This suggests that aprotinin does not directly enhance platelet function but instead probably has an indirect protective action. The aim of this study was to examine one such possible protective action, a prevention of heparin-mediated platelet inhibition. The method used to assess platelet function was hemostatometry, a technique that has the advantage of not requiring the use of anticoagulants and that has been used to demonstrate a possible association between inhibition of platelet function by heparin and postbypass hemorrhage [5]. Heparin has been demonstrated to bind directly to platelets [ll]. One way by which aprotinin may interfere with an inhibitory effect of heparin is by reducing this binding. This possibility was also explored in this study Accepted for publication Aug 21, 1992 Address reprint requests to Dr John, Department of Cardiothoracic Surgery, St. Bartholomew s Hospital, West Smithficld, London EClA 7BE, England. by examining the binding of tritium-labeled heparin to activated and nonactivated platelets with and without the presence of aprotinin. Material and Methods The following products were used in this study: Heparin (Monoparin-heparin sodium mucous [porcine]; CP Pharmaceuticals Ltd, Wrexham, UK) Aprotinin (Trasylol; Bayer, Leverkusen, Germany) Tritium-labeled heparin sodium salt {3H(G)}(NEN Products, Du Pont, Stevenage, UK) Adenosine diphosphate (Sigma, Watford, UK) Hemostatometry The hemostatometer is a recently developed method for assessing platelet function that has previously been described in detail [12, 131. Two and a half milliliters of non-anticoagulated blood is perfused through polyethylene tubing by paraffin oil displacement, a technique that has been shown to cause no measurable platelet damage. A hole is punched through the tubing, resulting in bleeding and a pressure drop. The pattern of pressure recovery shows the formation of hemostatic plugs in the holes. The initial recovery of the pressure represents platelet plug formation due to activation of platelets by shear stress and release of adenosine diphosphate from the shear-damaged platelets and red blood cells, and the later recovery is due to the stabilization of the platelet plug secondary to thrombin and fibrin formation such that it can resist the increasing pressure. The hemostasis curve is recorded and its area analyzed as H (mm Hg * s). The greater the value of H, the greater the relative inhibition of platelet function. As the blood is not anticoagulated, hemostasis is followed by coagulation manifested as a rapid pressure drop. The dynamic coagulation time is the time from the start of the measurement to the final pressure drop to zero by The Society of Thoracic Surgeons /93/$6.00
2 1176 JOHN ET AL AM Thorac Surg 1993;55: Platelet function was assessed by hemostatometry of the following blood samples from 35 cardiac surgical patients: Study 1 (n = 10): native blood alone; native blood with aprotinin (4 pmovl; and native blood with saline solution (equivalent volume to aprotinin). This study examined the direct in vitro effect of aprotinin on platelet function. Study 2 (n = 25): native blood alone; native blood with heparin (5 U/mL) and with aprotinin (4 pmovl); and native blood with heparin (5 U/mL) and with saline solution. This study examined the in vitro effect of aprotinin on the inhibition of platelet function by heparin. Radiolabeled Heparin Binding to Activated and Nonactivated Platelets Ten milliliters of citrated venous blood was withdrawn from each patient (1 ml of 3.8% trisodium citrate solution). To 5 ml of the citrated blood, aprotinin (4 pmol/l) was added, and to the other 5 ml, an equivalent volume of saline solution. Both samples were placed in a slowspeed rotator (26 rpm) for 10 minutes. Tritium-labeled heparin was added to each sample (2.4 pci), and the samples were again placed in the slow-speed rotator for 10 minutes and then centrifuged at 800 rpm for a further 10 minutes. One and a half milliliters of platelet-rich plasma was withdrawn from each sample. Two hundred microliters of the platelet-rich plasma was measured for radioactivity (after the addition of a tissue solubilizer [Solvease; BDH Chemicals, Poole, UK] and scintillation fluid [PCS; Amersham International, Amersham, UK]) and 100 pl was used for a platelet count estimation by spectrophotometry. One milliliter of platelet-rich plasma underwent high-speed centrifugation (12,000 rpm) for 5 minutes. Two hundred microliters of plasma was measured for radioactivity, and a relative platelet count was performed on 100 pl. The difference in the radiation count (Beckman LS 6000 IC p scintillation counter) between the platelet-rich plasma and the plasma samples was that due to plateletbound tritium-labeled heparin. To estimate relative platelet counts accurately in relatively small volumes, a spectrophotometer (UV-Visible Spectrophotometer, M330; Cam.Spec. Ltd, Cambridge, UK) was used at a wavelength of 540 nm. The difference in the spectrophotometric measurements between equivalent platelet-rich plasma and plasma specimens was a measure of the relative platelet count for which the radioactivity of the platelet-bound tritium-labeled heparin had been measured. To compare differences in heparin binding between different specimens and patients, the radioactivity counts were corrected to the equivalent platelet count for a spectrophotometric measurement of 1.0 at 540 nm. Binding studies were performed on 50 cardiac surgical patients as follows: Study 3 (n = 25): Measurements were made as described of platelet-bound tritium-labeled heparin in Table 1. Examination of Direct Effect of Aprotinin on Platelet Function In Vitro Variable Saline P (n = 10) Solution Aprotinin Value H (mm Hg * s) 2,298 f 480 3,008 k 609 NS CT (min) 16.9 f f a Data are shown as the mean * the standard error of the mean. CT = coagulation time; H = hemostatometry measurement; NS = not significant. the presence of aprotinin (4 -om) or an equivalent volume of saline solution. Study 4 (n = 25): Measurements were made as for study 3 but with the addition of adenosine diphosphate (30 pl/ml) to activate the platelets before high-speed centrifugation. Studies 3 and 4 examined in vitro the effect of aprotinin on the binding of tritium-labeled heparin to nonactivated and activated platelets, respectively. Study Population The study population was composed of cardiac surgcal patients from whom measurements were obtained either in the week before cardiac operation or within 1 year postoperatively. Eighty-five percent were male, and the mean age was 54.9 years. Of the patients, 71% were taking aspirin; 37%, calcium antagonists; and 8%, dipyridamole. Although they were on a regimen of antiplatelet medication, cardiac surgical patients were used, as this is a population in whom the hemostatic effects of aprotinin have been reported. All patients gave informed consent. Statistical Analysis The hemostatometric variable H was approximated to a normal distribution using log-transformed data. For radioactivity measurements, the raw data were used. Comparisons were made using Student s t test. Data are presented as the mean 2 the standard error of the mean. Results Study 1: Efect of Aprotinin on Platelet Function in Vitro No significant difference in platelet reactivity as measured by hemostatometry was shown between blood containing aprotinin or saline solution. Coagulation time was significantly prolonged in blood containing aprotinin (Table 1). Study 2: Effect of Aprotinin on Platelet Function in the Presence of Heparin A wide individual variation in platelet inhibition has been measured by hemostatometry [5]. A severe inhibition has been defined as R greater than 10, where R = H with heparidh without heparin. The presence of aprotinin significantly (p = 0.04) reduced this inhibition (Fig l), and this reduction was particularly significant (p = 0.003) in
3 Ann Thorac Surg 1993:jj: JOHN ET AL 1177 the subgroup with severe platelet inhibition by heparin (R > 10, or H >,000) (Fig 2). Figure 3 is an example of two hemostasis curves from identical blood containing heparin (5 U/mL) with aprotinin (4 pmoyl) or an equivalent volume of saline solution. Studies 3 and 4: Efect of Aprotinin on Heparin Binding to Nonactivated and Activated PZateIets There was a significant reduction in tritium-labeled heparin bound to both nonactivated ( p = 0.004) and activated platelets (p < ) in blood samples with aprotinin (4 pmol/l) compared with an equivalent volume of saline solution (Table 2). There was a significant difference in platelet-bound tritium-labeled heparin between activated and nonactivated platelets. This was substantially less significant (p = 0.04) with added aprotinin (4 pmoyl) than without it ( p = ). H (mmhg.s)~lo-~ H (mrn Hg.4 x ~ O - ~ 30 / A A P =Om04 B (Paired t test) Fig I. Hemostatometric nieasirrements (H) from (A) blood containing heparin with saline solution and (B) blood containing heparin with aprotinin (n = 25). Shaded areas represent the mean t the standard error of the mean. P = (Paired t test) Fig 2. Hemostatometric measurements (H) from (A) blood containing heparin with saline solution and (B) blood containing heparin with aprotinin in the subgroup demonstrating seuere platelet inhibition with heparin (n = 7). Shaded areas represent the mean? the standard error of the mean. Comment Aprotinin reduces blood loss after cardiopulmonary bypass. This has been reported for first-time operative procedures, redo procedures, and patients with endocarditis [6-8]. A number of suggestions have been made as to the mechanism for this hemostatic action. Aprotinin undoubtedly has an antifibrinolytic action, and this has been suggested as the relevant mechanism [8]. However, others [6, 14-16] have disputed the importance of hyperfibrinolysis as a cause of bleeding after bypass. Another suggestion has been that aprotinin prevents the activation and consumption of clotting factors by released proteases. Aprotinin has previously been shown [17] to inhibit rather than promote coagulation, a finding confirmed in the present study. This observation is interesting in view of the current controversy over thrombotic
4 1178 JOHN ET AL Ann Thorac Surg 1993;55:11759 Pressure (mm Hg) I Time (mind I Time (mind Fig 3. Hemostasis curves demonstrating a reduction of heparin-induced platelet inhibition in the presence of aprotinin: (A) blood containing heparin with saline solution and (B) blood containing heprlrin with aprotinin. events in patients receiving aprotinin. However, an anticoagulant effect is unlikely to account for a clinical hemostatic effect. The principal cause of the bleeding diathesis secondary to cardiopulmonary bypass has largely been attributed to a transient and severe defect in platelet function 11, 181. Modification of this platelet dysfunction may be a possible mode of action for the drug. Such a mechanism was supported by the observation of a significantly shorter prolongation of the skin bleeding time during cardiopulmonary bypass in the presence of aprotinin [7]. Prevention of platelet activation as assessed by reduction in thromboxane release has also been reported [19], as has the prevention of the loss of platelet membrane surface glycoprotein GpIb [IS]. Theoretically aprotinin may modify acquired platelet dysfunction either by a direct action enhancing platelet function or by an indirect action preventing inhibition of platelet function by damaging consequences of a cardiac operation. To date, there has been no reported evidence of aprotinin directly enhancing platelet function when tested in vitro. This study using the technique of hemostatometry also failed to demonstrate such a direct action. Therefore, if modification of platelet dysfunction by aprotinin is relevant to its hemostatic action, then it is most likely due to an indirect action protecting platelets from inhibition. Possible indirect actions include protection of platelets from plasmin, which has been observed to remove GpIb from platelets [ZO], and the reduction of factor XI1 and complement activation together with lysosomal enzyme release and the consequent destruction of von Willebrand factor and platelet membrane receptors [21]. However, the observation that a single dose of aprotinin at the commencement of cardiopulmonary bypass may be as effective as a continuous infusion [] is difficult to reconcile with the view that aprotinin acts as a hemostatic agent by preventing protease-mediated platelet damage or the consequences of complement activation, as protease release and complement activation occur throughout bypass. This suggests the possibility that there are other inhibitors of platelet function that aprotinin may protect against and that have not previously been appreciated. One such possible inhibitor is heparin, which is an essential prerequisite for cardiopulmonary bypass. It has recently been demonstrated using hemostatometry that an inhibition of platelet function by heparin is a probable etiological factor in hemorrhage after a cardiac operation [5]. In the present study, it has been demonstrated (again by hemostatometry) in vitro that aprotinin significantly reduced this inhibition. Therefore we suggest that interference with heparin-induced inhibition of platelet function may be one of the hemostatic actions of aprotinin in cardiac operations. How heparin modifies platelet function is unknown, but one possibility is that it is secondary to a direct binding of heparin to platelets. There is substantial evidence of such a direct binding both to nonactivated and especially to activated platelets [ll, 221. It has also been reported that aprotinin can bind to the platelet membrane [23]. In addition, aprotinin can bind directly to acidic glycoproteins, including heparin [24, 251, possibly as a result of its high basicity. These binding properties suggest that one way by which aprotinin could interfere with the interaction between heparin and platelets is by reducing the binding of the former to the latter. This possibility is strongly supported by the present study, which has clearly demonstrated a significant reduction in the bind- Table 2. Examination of Effect of Aprotinin on Binding of Tritium-Labeled Heparin to Activated and Nonactivated Platelets Corrected Corrected Radioactivity Radioactivity Count, Added Count, Added Variable Saline Solution (CPM) Aprotinin P M ) PI Value Nonactivated 19,378 t 3,766 8, , platelets (n = 25) Activated 42, ,774, , platelets (n = 25) pz Value a Data are shown as the mean? the standard error of the mean y, value = significance of difference between samples containing saline solution and those with aprotinin (activated and nonactivated); p2 value = significance of difference between activated and nonactivated platelets (with saline solution or aprotinin).
5 Ann Thorac Surg 1993;55: JOHN ET AL 1179 ing of tritium-labeled heparin to both nonactivated and activated platelets. In summary, the findings of this study were as follows: No significant direct enhancement of platelet function by aprotinin alone as assessed in vitro by hemostatometry. Significant reduction in heparin-associated platelet inhibition by aprotinin as assessed in vitro by hemosta tometry. Direct binding of tritium-labeled heparin to platelets, significantly more so to activated than nonactivated platelets. Significant reduction in binding of tritium-labeled heparin both to activated and nonactivated platelets by aprotinin. We conclude that a hemostatic action of aprotinin in cardiac operations may be to reduce the inhibition of platelets by heparin. It is probable that it does so by reducing the direct binding of heparin to platelets, especially to activated platelets, which may be a consequence of cardiopulmonary bypass [4]. A practical implication of these observations is the possibility of identifying those individuals who would most benefit from the use of aprotinin during a cardiac operation, ie, those who preoperatively demonstrate severe in vitro inhibition of platelet function that is due to heparin. This may also be relevant for patients who are heparinized for other than cardiac surgical reasons where hemorrhage as a major complication has long been recognized [26] and in whom the use of aprotinin may be potentially beneficial. This work was partly supported by the Joint Research Board of St. Bartholomew's Hospital. References Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:82&34. Talamonti MS, LoCicero J, Hoyne WP, Sanders JH, Michaelis LL. Early reexploration for excessive postoperative bleeding lowers wound complication rates in open heart surgery. Am Surg 1987;53:1024. Mammen EF, Koets MH, Washington BC, et al. Hemostasis changes during cardiopulmonary bypass. Semin Thromb Hemost 1985;11: Colman RW. Platelet and neutrophil activation in cardiopulmonary bypass. Ann Thorac Surg 1990;49:32-4. John LCH, Rees GM, Kovacs IB. Inhibition of platelet function by heparin: an etiological factor in post bypass hemorrhage. J Thorac Cardiovasc Surg (in press). Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat openheart surgery. Lancet 1987;2: Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97: Have1 M, Teufelsbauer H, Knob1 P, et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 1991;101: Mc Nicol GP, Prentice CRM, Douglas AS. Trasylol and failure in hemostasis. In: Donatelli R, ed. Proteases and antiproteases in cardioangiology. Stuttgart/New York: FK Schattauer Verlag, 1970: Aoki N, Naito K, Yoshida N. Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation. Blood 1978;52: Horne MK, Chao SC. Heparin binding to resting and activated platelets. Blood 1989;74: Kovacs IB, Hutton RA, Kernoff PBA. Hemostatic evaluation in bleeding disorders from native blood: clinical experience with the Hemostatometer. Am J Clin Pathol 1989;91: Ratnatunga CP, Rees GM, Kovacs IB. Preoperative hemostatic activity and excessive bleeding after cardiopulmonary bypass. Ann Thorac Surg 1991;52: Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76: Van Oeveren W, Harder MR, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99: Harker LA. Bleeding after cardiopulmonary bypass. N Engl J Med 1986;314: De Smet AE, Joen MCN, van Oeveren W, et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 1990;100: Zilla P, Fasol R, Groscurth P, Klepetko W, Reichenspurner H, Wolner E. Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation rather than continual activation. J Thorac Cardiovasc Surg 1989; Van Oeveren W, Jansen NJG, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44: Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 1985;65: Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotininpreliminary results. Thorac Cardiovasc Surg 1989; Sobel M, Adelman B. Characterization of platelet binding of heparin and other glycosaminoglycans. Thromb Res 1988;50: Kiernan JA, Stoddart RW. Fluorescent-labelled aprotinin: a new reagent for the histochemical detection of acid muco substances. Histochemie 1973;34: Stoddart RW, Kiernan JA. Aprotinin, a carbohydrate-binding protein. Histochemie 1973;34: Heine H, Forster FJ, Neufahrt A. Zur Wechselwirkung zwischen dem basischen Polvpeptid Trasvlol und Proteoglvkanen. IV. lntrazellulare binding. Med Welt 1976;27177L Levine MN, Hirsh J. Hemorrhagic complications of anticoagulant therapy. Semin Thromb Hemost 1986;12:39-57.
Platelet Protection by Low-Dose Aprotinin in Cardiopulmonary Bypass: Electron Microscopic Study
Platelet Protection by Low-Dose Aprotinin in Cardiopulmonary Bypass: Electron Microscopic Study Jacob Lavee, MD, Zvi Raviv, MD, Aram Smolinsky, MD, Naphtali Savion, PhD, David Varon, MD, Daniel A. Goor,
More informationP childhood, and the ability to correct even complicated
Aprotinin in Pediatric Cardiac Operations: Platelet Function, Blood Loss, and Use of Homologous Blood Joachim Boldt, MD, Christoph Knothe, MD, Bernfried Zickmann, MD, Niels Wege, Friedhelm Dapper, MD,
More informationHemostasis Haemostasis means prevention of blood loss from blood vessels.
١ Hemostasis Haemostasis means prevention of blood loss from blood vessels. Bleeding is stopped by several mechanisms, which are: 1. Local vasoconstriction 2. Formation of platelet plug 3. Blood coagulation
More informationHemostasis Haemostasis means prevention of blood loss from blood vessels.
1 Hemostasis Haemostasis means prevention of blood loss from blood vessels. Bleeding is stopped by several mechanisms, which are: 1. Local vasoconstriction 2. Formation of platelet plug 3. Blood coagulation
More informationHemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins
Hemostasis Learning objectives 14-16 Dr. Mária Dux Components: blood vessel wall thrombocytes (platelets) plasma proteins Hemostatic balance! procoagulating activity anticoagulating activity 1 Thrombocytes
More informationI bypass (CPB) circuit causes platelet damage and impairment
Aprotinin Reduces Intraoperative and Postoperative Blood Loss in Membrane Oxygenator Cardiopulmonary Bypass Marcel P. Harder, MD, Leon Eijsman, MD, Klaas J. Roozendaal, MD, Willem van Oeveren, PhD, and
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Petričević M., Biočina B., Boban M., Zrno Mihaljević M., White A., Rotim C., Subašić A., Miličić Davor. (2015) Clinical relevance and practical value of platelet function
More informationPostoperative Aprotinin: Effect on Blood Loss and Transfusion Requirements in Cardiac Operations
Postoperative Aprotinin: Effect on Blood Loss and Transfusion Requirements in Cardiac Operations Serta~ (~i~ek, MD, Ufuk Demirkili~, MD, Erkan Kuralay, MD, Ertugrul Ozal, MD, and Harun Tatar, MD Department
More informationPlatelet dysfunction in acute type A aortic dissection evaluated by the laser light-scattering method
Platelet dysfunction in acute type A aortic dissection evaluated by the laser light-scattering method Masashi Tanaka, MD Koji Kawahito, MD Hideo Adachi, MD Takashi Ino, MD Objectives: Platelet dysfunction
More informationPhysiology of. The Blood hemostasis. By prof. Israa f. jaafar
Physiology of The Blood hemostasis By prof. Israa f. jaafar Learning objectives Understand the Platelet structure and function Explane the Platelet production Understand the phases of hemostasis: vascular
More informationApproach To A Bleeding Patient
ABDUL MAJEED, RAHUL RAJEEV REVIEW ARTICLE INTRODUCTION Hemostasis is the process of forming clots in the walls of damaged blood vessels and preventing blood loss while maintaining blood in a fluid state
More informationL iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche
L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University
More informationΔοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Εμμανουήλ Βαβουρανάκης
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Εμμανουήλ Βαβουρανάκης Αναπλ. Καθηγητής Καρδιολογίας Ιπποκράτειο ΓΝΑ Haematology Research Laboratory!! Platelets Small anucleate discoid cells Involved
More informationThe decision to discontinue aspirin preoperatively in
Effect of Preoperative Aspirin Use on Mortality in Coronary Artery Bypass Grafting Lawrence J. Dacey, MD, John J. Munoz, MD, Edward R. Johnson, MD, Bruce J. Leavitt, MD, Christopher T. Maloney, MD, Jeremy
More informationAprotinin Inhibits Protease-Dependent Platelet Aggregation and Thrombosis
Aprotinin Inhibits Protease-Dependent Platelet Aggregation and Thrombosis Tanveer A. Khan, MD, Cesario Bianchi, MD, PhD, Pierre Voisine, MD, Jennifer Sandmeyer, BS, Jun Feng, MD, PhD, and Frank W. Sellke,
More informationEDUCATIONAL COMMENTARY PLATELET DISORDERS
EDUCATIONAL COMMENTARY PLATELET DISORDERS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn
More informationCoagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University
In The Name God Coagulation an Overview Dr.Abdolreza Afrasiabi Thalassemia & Heamophilia Genetic Research hcenter Shiraz Medical University Bleeding Clotting Hemostasis Review of platelet function Platelets
More informationCh. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma
Chapt. 45 Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma Inheritance of X-linked gene for Factor VIII hemophilia A Explain the
More informationCLOTTING AND FIBRINOLYTIC DISTURBANCE DURING LUNG TRANSPLANTATION: EFFECT OF LOW-DOSE APROTININ
CLOTTING AND FIBRINOLYTIC DISTURBANCE DURING LUNG TRANSPLANTATION: EFFECT OF LOW-DOSE APROTININ Y. J. Gu, MD, PhD J. de Haan, PhD U. P. M. Brenken, MD, PhD W. J. de Boer, MD Jm. Prop, MD, PhD W. van Oeveren,
More informationActivation of the Protein C System During Cardiopulmonary Bypass With and Without Aprotinin
Activation of the Protein C System During Cardiopulmonary Bypass With and Without Aprotinin Ron G. H. Speekenbrink, MD, Rogier M. Bertina, PhD, Francisco España, PhD, Charles R. H. Wildevuur, MD, PhD,
More informationHemostasis and Thrombosis
Hemostasis Hemostasis and Thrombosis Normal hemostasis is a consequence of tightly regulated processes that maintain blood in a fluid state in normal vessels, yet also permit the rapid formation of a hemostatic
More informationOral Anticoagulant Drugs
Oral Anticoagulant Drugs Spoiled sweet clover caused hemorrhage in cattle(1930s). Substance identified as bishydroxycoumarin. Initially used as rodenticides, still very effective, more than strychnine.
More informationWarfarin Cessation Before Cardiopulmonary Bypass: Lessons Learned from a Randomized Controlled Trial of Oral Vitamin K
Warfarin Cessation Before Cardiopulmonary Bypass: Lessons Learned from a Randomized Controlled Trial of Oral Vitamin K Richard P. Whitlock, MD, Mark A. Crowther, MD, Theodore E. Warkentin, MD, Mary-Helen
More informationNEW ONE-STAGE PROCEDURES FOR THE QUANTITATIVE DETERMINATION OF PROTHROMBIN AND LABILE FACTOR*
NEW ONE-STAGE PROCEDURES FOR THE QUANTITATIVE DETERMINATION OF PROTHROMBIN AND LABILE FACTOR* MARIO STEFANINI, M.D.f From the Department ofbiochemistry, Marquette University School of Medicine, Milwaukee,
More informationECMO vs. CPB for Intraoperative Support: How do you Choose?
ECMO vs. CPB for Intraoperative Support: How do you Choose? Shaf Keshavjee MD MSc FRCSC FACS Director, Toronto Lung Transplant Program Surgeon-in-Chief, University Health Network James Wallace McCutcheon
More informationCoagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU
Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate
More informationDIAGNOSTIC TESTING IN PATIENT BLOOD MANAGEMENT PROGRAMS
DIAGNOSTIC TESTING IN PATIENT BLOOD MANAGEMENT PROGRAMS The Role of Diagnostic Point-of-Care Testing Diagnostic testing is an essential component of Patient Blood Management. The accurate assessment of
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationM B Garvey. University of Toronto
Do I really need that test??? M B Garvey Professor Emeritus University of Toronto St Michael s Hospital No relevant conflicts of interest 1 HEMOSTASIS IS LIKE LOVE Everybody talks about it, nobody understands
More informationSeparation of Plasma and Serum and Their Proteins from Whole Blood
Separation of Plasma and Serum and Their Proteins from Whole Blood BCH 471 [Practical] BLOOD COMPOSITION Other names to blood cells Red blood cells (erythrocytes) White blood cells (leukocytes) Platelets
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationMayor lung resection in the presence of anti-platelet therapy. Hans-Beat Ris Service de Chirurgie Thoracique CHUV, Lausanne
Mayor lung resection in the presence of anti-platelet therapy Hans-Beat Ris Service de Chirurgie Thoracique CHUV, Lausanne THORACIC SURGERY IN THE PRESENCE OF ANTI-PLATELET THERAPY Charybdis: Thrombosis
More informationIntraoperative Use of Epsilon Pratiti C et al 273
Intraoperative Use of Epsilon Pratiti C et al 273 ORIGINAL ARTICLE Intraoperative Use of Epsilon Amino Caproic Acid and Tranexamic Acid in Surgeries Performed Under Cardiopulmonary Bypass: a Comparative
More informationHemostatic System - general information
PLATELET DISORDERS Hemostatic System - general information Normal hemostatic system vessel wall circulating blood platelets blood coagulation and fibrynolysis Bleeding Diathesis inherited or acquired defects
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationHow can ROTEM testing help you in cardiac surgery?
How can ROTEM testing help you in cardiac surgery? Complicated bleeding situations can appear intra and post operatively. They can be life-threatening and always require immediate action. A fast differential
More informationInstruments smart solutions & service IGZ Instruments AG Räffelstrasse 32 CH 8045 Zürich
ADP (Adenosine-5 -Diphosphate) 101312 3 x 0.5mL ADP is a lyophilized preparation of adenosine-5 -diphosphate. The working concentration of the reconstituted reagent is 2 x 10-4 M. ADP is for use in routine
More informationDISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital
DISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital Disseminated intravascular coagulation (DIC) Disseminated
More informationComparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery
Butler Journal of Undergraduate Research Volume 2 Article 24 2016 Comparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery Lisa K. LeCleir Butler University, lisa.lecleir@gmail.com
More informationNew data for preventing postoperative hemorrhage with the use of aprotinin
New data for preventing postoperative hemorrhage with the use of aprotinin Nikolaos BAIKOUSSIS MD, MSc, PhD Cardiac Surgeon Ippokrateio General Hospital of Athens No conflict of interest Bleeding
More informationApproach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate
Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:
More informationMANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY
MANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY 19th ANNUAL CONTROVERSIES AND PROBLEMS IN SURGERY Thabo Mothabeng General Surgery: 1 Military Hospital HH Stone et al. Ann Surg. May 1983; 197(5):
More informationFresh Blood Units Contain Large Potent Platelets That Improve Hemostasis After Open Heart Operations
Fresh Blood Units Contain Large Potent Platelets That Improve Hemostasis After Open Heart Operations Rephael Mohr, MD, Daniel A. Goor, MD, Alon Yellin, MD, Yaron Moshkovitz, MD, Ami Shinfeld, MD, and Uri
More informationThyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A.
UvA-DARE (Digital Academic Repository) Thyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A. Link to publication Citation for published version (APA): Squizzato, A.
More informationLVAD Complications, Recovery
LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,
More informationJohn Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationCABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin
CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin DISCLOSURES None Objective(s): Our department routinely used
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationBLEEDING DISORDERS Simple complement:
BLEEDING DISORDERS Simple complement: 1. Select the statement that describe the thrombocytopenia definition: A. Marked decrease of the Von Willebrandt factor B. Absence of antihemophilic factor A C. Disorder
More informationDiagnostic, Technical and Medical
Diagnostic, Technical and Medical Approaches to Reduce CABG Related Stroke Pieter Kappetein, Michael Mack, M.D. Dept Thoracic Surgery, Rotterdam, The Netherlands Baylor Healthcare System Dallas, TX Background
More informationUniversity of Pennsylvania Health System Aprotinin Task Force
Aprotinin Use in Adult Cardiac Surgery: A Recommendation Statement from the University of Pennsylvania Health System Center for Evidence-based Practice *Note: This guideline was originally released on
More informationHemostasis and thrombosis in patients with liver disease. Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands
Hemostasis and thrombosis in patients with liver disease Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands Importance of the liver in hemostasis Synthesis of Coagulation factors Fibrinolytic proteins
More informationHemostasis and Blood Forming Organs
Hemostasis and Blood Forming Organs Subcommittee: Williams, Patricia B. (Chair) pbwillia@umich.edu McMillan, David dcmcmillan@unmc.edu Dobrydneva, Yuliya dobrydy@evms.edu DEFEROXAMINE FERROUS SULFATE ferrous
More informationPart IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
More informationPICT ANTICOAGULANT MONITORING 1. PEFAKIT PICT. Clotting Assay. PEFAKIT PiCT. PEFAKIT PICT Calibrators UFH. PEFAKIT PICT Controls UFH
1 2 3 4 PEFAKIT PiCT PEFAKIT PICT Calibrators UFH PEFAKIT PICT Controls UFH PEFAKIT PICT Calibrators LMWH Clotting Assay PICT 1. PEFAKIT PICT Package size 8-505-01 kit 80 3 vials of PiCT Activator (2mL)
More informationEDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION
EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/37409 holds various files of this Leiden University dissertation Author: Engbers, Marissa Title: Conventional and age-specific risk factors for venous thrombosis
More informationHemostasis and. Blood Coagulation
Hemostasis and Blood Coagulation Events in Hemostasis The term hemostasis means prevention of blood loss. Whenever a vessel is severed or ruptured, hemostasis is achieved by several mechanisms: (1) vascular
More informationWhen Should I Use Tranexamic Acid for Children? Dr Andrea Kelleher Consultant Adult and Paediatric Cardiac Anaesthetist
When Should I Use Tranexamic Acid for Children? Dr Andrea Kelleher Consultant Adult and Paediatric Cardiac Anaesthetist When? When a drug is licenced for (the proposed) use When its use is supported by
More informationHeme (Bleeding and Coagulopathies) in the ICU
Heme (Bleeding and Coagulopathies) in the ICU General Topics To Discuss Transfusions DIC Thrombocytopenia Liver and renal disease related bleeding Lack of evidence in managing critical illness related
More informationThromboelastograph (TEG ) Utilization in Blood Management. Tim Shrewsberry, BS, CCP Firelands Regional Medical Center, Sandusky, OH
Thromboelastograph (TEG ) Utilization in Blood Management Tim Shrewsberry, BS, CCP Firelands Regional Medical Center, Sandusky, OH TEG Hemostasis System ROTEM Delta Whole blood Hemostasis Analyzer Personalized
More informationBlood Management of the Cardiac Patient in the Postoperative Period
Blood Management of the Cardiac Patient in the Postoperative Period Al Stammers, MSA, CCP, Eric Tesdahl, PhD Andy Stasko MS, CCP, RRT, Linda Mongero, BS, CCP, Sam Weinstein, MD, MBA Goal To examine the
More informationY. Helen Zhang, MD Andy Nguyen, MD 10/28/2012
Y. Helen Zhang, MD Andy Nguyen, MD 10/28/2012 Clinical History Patient: 23-year-old female Clinical course: status-post cholecystectomy, complicated by retained common bile duct stones. Following three
More informationThe Effects of Cardiopulmonary Bypass with Hollow Fiber Membrane Oxygenator on Blood Clotting Measured by Thromboelastography
Physiol. Res. 51: 145-150, 2002 The Effects of Cardiopulmonary Bypass with Hollow Fiber Membrane Oxygenator on Blood Clotting Measured by Thromboelastography M. HORÁČEK, K. CVACHOVEC Department of Anesthesiology
More information2010, Metzler Helfried
Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What
More informationIntra-operative Effects of Cardiac Surgery Influence on Post-operative care. Richard A Perryman
Intra-operative Effects of Cardiac Surgery Influence on Post-operative care Richard A Perryman Intra-operative Effects of Cardiac Surgery Cardiopulmonary Bypass Hypothermia Cannulation events Myocardial
More informationBLEEDING AND USE OF BLOOD PRODUCTS AFTER HEART OPERATIONS IN INFANTS
BLEEDING AND USE OF BLOOD PRODUCTS AFTER HEART OPERATIONS IN INFANTS From Children's Hospital, University of Helsinki, Finland. Received for publication March 10, 1994. Accepted for publication July 29,
More informationWHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT WO NDCLOT. The WoundClot Principals for Effective Bleeding Control PRESENTATION
WHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT ARTICLES OUR STUDY BLEEDING CONTROL 5 POINT MODEL WO NDCLOT The WoundClot Principals for Effective Bleeding Control PRESENTATION Harnessing SCIENCE
More informationPlatelet Disorders. By : Saja Al-Oran
Platelet Disorders By : Saja Al-Oran Introduction The platelet arise from the fragmentation of the cytoplasm of megakaryocyte in the bone marrow. circulate in the blood as disc-shaped anucleate particles
More informationPreoperative antithrombotic management: before cardiac surgery. S. Demertzis
Preoperative antithrombotic management: before cardiac surgery S. Demertzis Facts > CABG-related bleeding complications & perioperative acute coronary events are strongly influenced by the management of
More informationCoagulation Defects and Bleeding in Open-Heart Surgery
Coagulation Defects and Bleeding in Open-Heart Surgery Enrique E. Signori, M.D., John A. Penner, M.D., and Donald R. Kahn, M.D. H emorrhagic diathesis associated with extracorporeal circulation has been
More informationM undergoing coronary artery bypass grafting
Comparison of Blood Reinfusion Techniques Used During Coronary Artery Bypass Grafting Victor A. Ferraris, MD, PhD, William R. Berry, MD, and Robert R. Klingman, MD Division of Cardiothoracic Surgery, Albany
More informationKumi Fukuhara *, Takashi Kondo, Hirotsugu Miyoshi, Hiroshi Hamada and Masashi Kawamoto
Fukuhara et al. JA Clinical Reports (2019) 5:3 https://doi.org/10.1186/s40981-019-0224-3 CASE REPORT Open Access Rotational thromboelastometry-guided perioperative management of coagulation in a patient
More information5/30/2013. I have no conflicts of interest to disclose. Alicia Privette, MD Trauma & Critical Care Fellow. Trauma = #1 cause of death persons <40 yo 1
I have no conflicts of interest to disclose. Alicia Privette, MD Trauma & Critical Care Fellow Trauma = #1 cause of death persons
More informationIntroduction to coagulation and laboratory tests
Introduction to coagulation and laboratory tests Marc Jacquemin Special Haemostasis Laboratory Center for Molecular and Vascular Biology University of Leuven Coagulation in a blood vessel: fibrin stabilises
More informationDIC. Bert Vandewiele Fellow Critical Care 23 May 2011
DIC Bert Vandewiele Fellow Critical Care 23 May 2011 Dissiminated Intravascular Coagulopathie 11/3/2011 Dr. Bert Vandewiele 2 Dissiminated Intravascular Coagulopathie = Consumption coagulopathie = Defibrination
More informationHemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.
Hemodynamic Disorders, Thrombosis, and Shock Richard A. McPherson, M.D. Edema The accumulation of abnormal amounts of fluid in intercellular spaces of body cavities. Inflammation and release of mediators
More informationMultiplate analyzer Cut-off-values ADPtest and ASPItest
Multiplate analyzer Cut-off-values ADPtest and ASPItest Cut-off values ADPtest The cut-off values were established in hirudin blood samples. Healthy individuals AUC (U) 1 Patient on ADP receptor antagonist
More informationPhotopheresis Technical Challenges. Lindsay Palomino, BSN RN HP May 6, 2016
Photopheresis Technical Challenges Lindsay Palomino, BSN RN HP May 6, 2016 No relevant disclosures SCCA Apheresis Unit! Therakos CellEx Photopheresis System For technical challenges and troubleshooting:
More informationBoston City Hospital, and the Department of Medicine, Harvard Medical School, Boston)
THE EFFECT OF FOREIGN SURFACES ON BLOOD COAGULATION ", 2 BY EUGENE L. LOZNER AND F. H. L. TAYLOR WITH THE TECHNICAL ASSISTANCE OF HARRIET MAcDONALD (From the Thorndike Memorial Laboratory, Second and Fourth
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationC CONFERENCIAS MAGISTRALES Vol. 36. Supl. 1 Abril-Junio 2013 pp S31-S35 Bleeding following deep hypothermia and circulatory arrest in children Emad B Mossad, MD* * Division of Pediatric Cardiovascular
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationHemodialysis (HD) has improved the prospects of. Sonoclot Analysis in Cardiac Surgery in Dialysis- Dependent Patients
CARDIOVASCULAR Sonoclot Analysis in Cardiac Surgery in Dialysis- Dependent Patients Toshihiko Shibata, MD, PhD, Yasuyuki Sasaki, MD, PhD, Koji Hattori, MD, PhD, Hidekazu Hirai, MD, Mitsuharu Hosono, MD,
More information4/23/2009. September 15, 2008
The Current Treatment of Deep Venous Thrombosis: Are We Doing Enough? George H. Meier, MD Professor and Chief Division of Vascular Surgery University of Cincinnati College of Medicine Cincinnati, Ohio
More informationDr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN
Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN The student should be able:» To identify the mechanism of homeostasis and the role of vessels, platelets
More informationCurrent status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest
Anesthesiology Clin N Am 21 (2003) 527 551 Current status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest Jeffrey A. Green, MD*, Bruce D. Spiess, MD Department
More informationDubbi e certezze nella gestione delle emorragie con metodiche point-of-care
Sessione Educazionale 4 : Gestione del paziente emorragico Dubbi e certezze nella gestione delle emorragie con metodiche point-of-care P. Simioni Università di Padova hemostasis Vascular phase Platelet
More informationEffects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem Ò ): an in vitro study
British Journal of Anaesthesia 95 (3): 31 1 (5) doi:1.193/bja/aei197 Advance Access publication July 15, 5 Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography
More informationChapter 19 Cardiovascular System Blood: Functions. Plasma
Chapter 19 Cardiovascular System Blood: Functions 19-1 Plasma Liquid part of blood. Colloid: liquid containing suspended substances that don t settle out of solution 91% water. Remainder proteins, ions,
More informationChapter 3. Haemostatic abnormalities in patients with liver disease
Chapter 3 Haemostatic abnormalities in patients with liver disease Ton Lisman, Frank W.G. Leebeek 1, and Philip G. de Groot Thrombosis and Haemostasis Laboratory, Department of Haematology, University
More informationConsensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture
Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.
More informationRoutine preoperative coagulation tests: are they necessary?
Routine preoperative coagulation tests: are they necessary? Dr Azzah Alzahrani MD Pediatrics Hematology /Oncology PSMMS Outline Introduction. Brief review of hemostatic mechanisms. A clinical aspect of
More informationRandomized Study of Aprotinin and DDAVP to Reduce Postoperative Bleeding After Cardiopulmonary Bypass Surgery
921 Randomized Study of Aprotinin and DDAVP to Reduce Postoperative Bleeding After Cardiopulmonary Bypass Surgery Eduardo Rocha, MD; Francisco Hidalgo, MD; Rafael Llorens, MD; Jose M. Melero, MD; Jose
More informationA Guide To Safe Blood Transfusion Practice
A Guide To Safe Blood Transfusion Practice Marie Browett, Pavlina Sharp, Fiona Waller, Hafiz Qureshi, Malcolm Chambers (on behalf of the UHL Blood Transfusion Team) A Guide To Safe Blood Transfusion Practice
More informationSchematic Of Heparin Induced Thrombocytopenia Platelet Count
Schematic Of Heparin Induced Thrombocytopenia Platelet Count Normal IgG and IgG2 differentially inhibit HIT antibody-dependent platelet activation that platelet counts were lower in FcγRIIA 131RR patients
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More information